Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| For the seventh consecutive year, IQVIA was named one of the world's most admired companies in Fortune's annual survey |
| That really generally bodes well for the commercial business as our clients prepare for launching those drugs into the marketplace |
| We're happy about that because that's the fastest-growing therapeutic area, hands down all around |
| You saw that we had a good quarter |
| Again, the numbers showed numbers of RFPs, the pipeline at an all-time high, the qualified pipeline up strong double-digits and are going across the board |
| On the clinical side, demand from our R&DS clients remained strong |
| That actually was very, very strong in terms of bookings |
| As I said, our RFP flow was up 13% in Q4, and that's across the board, strong double-digits in EBP and in large pharma as well |
| Q4 was another strong quarter |
| R&DS delivered the second largest booking quarter in IQVIA history at over $2.8 billion, along with another quarter of double-digit RFC growth |
| Our EBITDA margin expanded by 60 basis points and adjusted diluted EPS was up 12% you exclude the year-over-year impact of interest rates and the increase in the UK tax rate |
| And again, EBP funding very strong, all-time high |
| As we close 2023, we're proud of what we have achieved in R&DS |
| The business booked $10.7 billion of net new business, including record high service bookings of $8.4 billion |
| We had the second highest bookings quarter ever and the first -- the one that was the highest, which was last year, I think that was -- we had a very big proportion of pass-through from specific large award |
| Free cash flow was strong in the quarter at $568 million, representing 109% of adjusted net income |
| And lastly, we issued full year 2024 guidance with underlying revenue growth of 5% to 7%, continued margin expansion and a resumption of EPS growth with adjusted diluted earnings per share expected to be up 7% to 10% |
| We are very proud at IQVIA of Christina's work and our passion for accelerating innovation in health care through the use of evidence-based decision-making |
| Now it's already reviewed, R&D Solutions delivered another really strong quarter of bookings |
| Our results in the quarter were slightly better than what we had expected |
| And in fact, our own market expectations of spend by pharma over the next few years, compares very favorably to the prior period |
| So that gives us comfort that the forecast is appropriately built and hopefully, we'll be -- we have upside favorability if things work out perfectly well |
| And we have strong relationships |
| Frankly, in our own engagement with customers in the recent past, we noted an improved customer sentiment during the quarter |
| I would just say that, by segment, the EBP segment was particularly strong |
| I mean, look, this continues to be pressure from clients and negotiate and tough negotiations that's been the biggest surprise for me over the past several years, and that is that you got a better mode, you've got a better company, a better delivery system, better capabilities, then we should be able to actually charge more |
| The qualified pipeline is up strong double-digits, again, across the board |
| On the respiratory virus response, including for influenza and RSV, identifying at-risk groups and improving overall population health |
| And you see in our EBITDA margins, they've actually continue to improve overall and that's with R&DS being over 50% of our revenue |
| Full year same thing, very strong and EBP even stronger for the full year |
| Statement |
|---|
| Now, a word of caution, the business saw a decline in growth through 2023 with every quarter being worse than the previous one |
| Finally, in CSMS revenue for the full year was $727 million, which was down 2.2% reported and 0.3% at constant currency |
| We saw headwinds in the more discretionary part of the TAS segment, which is the analytics and consulting business |
| The commercial side of our business continues, of course, to face the macro environment that we've described in the past as our clients remain cautious with their spending and their cost containment |
| But yes, in general, there has been -- there is some margin degradation as a result of the shift towards FSP |
| But on the R&DS side, we are experiencing the pressure, the more difficult environment with respect to pricing and negotiation and so on |
| CSMS revenue is expected to be approximately $700 million, which is down slightly year-over-year |
| In the quarter, COVID-related revenues were approximately $65 million, which was down about $125 million versus the fourth quarter of 2022 |
| Although, discretionary spending has not yet rebounded to the levels that we expect, they will, and it continues to be a headwind |
| I would point to you that going back a couple of years at least, people who are competitors "whining about EVP funding." and all see our stock suffered as a result of this whining, we kept telling the world that we weren't seeing it |
| The guidance also reflects the latest phasing of pass-through revenue which results in an additional headwind of approximately 100 basis points to R&DS year-over-year |
| They come with -- it's just an artificial accounting add to our -- but the fact our buildup forecast for 2024, pass-throughs will be a headwind to R&DS growth, and that represents 100 basis points approximately of headwind to top line growth of R&DS, again, inclusive of pass-throughs |
| Fourth quarter adjusted diluted EPS of $2.84 faced the continuing headwind of the step-up in interest expense and the UK corporate tax rate increase |
| I mean some of these companies have been in trouble |
| That represents a direct headwind to growth of 350 basis points to R&DS growth, 350 basis points |
| And you've seen our large cap companies that operate in the same business actually forecast even declining sales for their own businesses for 2024 |
| And then I guess a follow-up on the -- there's a lot of concern here |
| But perhaps because we've been hurt before, we've tried to be appropriately cautious in planning |
| And then there is a step that's more discretionary because it's more -- it's a longer cycle, the deceleration impacted our numbers more in Q3 and further in Q4 |
| And that represents approximately 350 basis points of headwind to the R&DS growth rate |
Please consider a small donation if you think this website provides you with relevant information